TIDMLMT

RNS Number : 4858E

Lombard Medical Technologies PLC

10 April 2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Lombard Medical Technologies PLC

("Lombard Medical", or "the Company")

Director/PDMR Shareholding

London, UK, 10 April 2014 - On 26 February 2014, Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair of abdominal aortic aneurysms, announced that it had published a circular which set out the Board of Directors' recommendations to, inter alia, reorganise the Lombard Medical Technologies Group pursuant to a Court approved scheme of arrangement (the "Scheme") so that Lombard Medical becomes a directly-owned subsidiary of Lombard Medical, Inc ("LM, Inc").

For the purpose of effecting the Scheme, Ian Ardill, Chief Financial Officer, transferred one of his ordinary shares of 20 pence each to LM, Inc. on 7 April 2014 at a price of 185 pence. His holding after the transfer was 8,572 shares of 20 pence each, representing 0.02% of the Company's issued shares.

-Ends-

For further information:

 
 Lombard Medical Technologies PLC       Tel: +44 (0)1235 750 800 
  Simon Hubbert, Chief Executive 
  Officer 
  Ian Ardill, Chief Financial Officer 
                                         Tel: +44 (0)1235 750 800 
  Lombard Medical, Inc 
  Simon Hubbert, Chief Executive 
  Officer 
  Ian Ardill, Chief Financial Officer 
 
 Canaccord Genuity Limited (Nomad)      Tel: +44 (0)20 7523 8000 
  Lucy Tilley / Tim Redfern / Henry 
  Fitzgerald O'Connor / Dr Julian 
  Feneley 
 
 FTI Consulting (UK)                    Tel: +44 (0) 203 727 1000 
  Simon Conway / Stephanie Cuthbert 
  / Victoria Foster Mitchell

About Abdominal Aortic Aneurysms ("AAA")

AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year over 500,000 new cases are diagnosed. In the US, aortic aneurysm disease is among the leading causes of death and it is estimated that 1.7 million people over the age of 55 have an abdominal aortic aneurysm.

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company focused on device solutions for the $1.4 billion per annum abdominal aortic aneurysm repair market. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Aorfix is the only stent graft approved for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. Aorfix is the first AAA stent graft not of US origin to gain US FDA approval. The Company is headquartered in Oxfordshire, England with US operations in Irvine, CA.

Further background on the Company can be found at www.lombardmedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBRGDSSXGBGSC

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Lombard Medical Technologies Charts.
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Lombard Medical Technologies Charts.